A 62-year-old man presents with painless gross hematuria for 3 weeks. He has a 40 pack-year smoking history and works as a chemical factory worker. Cystoscopy reveals a solitary, papillary lesion on the lateral wall of the bladder. Biopsy shows high-grade urothelial carcinoma confined to the lamina propria (stage T1). CT abdomen/pelvis shows no lymph node enlargement or distant metastases. After transurethral resection of bladder tumor (TURBT), what is the most appropriate next step in management?

Explanation

## Management of High-Grade T1 Bladder Cancer ### Clinical Context This patient has high-grade non-muscle-invasive bladder cancer (NMIBC) with lamina propria invasion (T1). The absence of muscle invasion and metastases makes him a candidate for bladder-preserving therapy. ### Treatment Algorithm for T1 High-Grade Disease ```mermaid flowchart TD A[TURBT + Biopsy confirms T1 HG]:::outcome --> B{Complete resection?}:::decision B -->|Yes| C[Risk stratification]:::action C --> D{High-risk NMIBC?}:::decision D -->|Yes| E[Intravesical BCG induction + maintenance]:::action D -->|No| F[Intravesical chemotherapy]:::action B -->|No| G[Re-TURBT within 2-6 weeks]:::action E --> H[Cystoscopy surveillance q3-6 months]:::action F --> H ``` ### Why Intravesical BCG is Correct **Key Point:** High-grade T1 urothelial carcinoma is classified as **high-risk NMIBC** and requires intravesical immunotherapy with Bacillus Calmette-Guérin (BCG), not chemotherapy alone. **High-Yield:** BCG is superior to intravesical chemotherapy for high-grade T1 disease because: - Reduces recurrence rate by ~40% - Reduces progression to muscle-invasive disease by ~27% - Mechanism: immune activation via TLR4 signaling **Clinical Pearl:** The standard induction regimen is weekly instillations for 6 weeks, followed by maintenance therapy (typically 3 weekly instillations at 3, 6, 12, 18, 30, and 36 months) in responders. This improves disease-free survival compared to induction alone. ### Risk Stratification for NMIBC | Feature | Low Risk | Intermediate Risk | High Risk | |---------|----------|-------------------|----------| | Grade | Low-grade | Mixed | High-grade | | Stage | Ta, T1 | Ta, T1 | T1, CIS | | Size | <3 cm | 3–5 cm | >5 cm or multifocal | | Multiplicity | Solitary | Few | Multiple/recurrent | | CIS | Absent | Absent | Present | | **Treatment** | **Chemotherapy or observation** | **Chemotherapy ± BCG** | **BCG induction + maintenance** | **Mnemonic:** **HiGH-RISK** = High-grade, Gemistocytic/CIS, Huge/multifocal, Recurrent, Invasive (T1), Solitary CIS, Kb (BCG indicated) ### Why Re-TURBT May Be Needed Up to 50% of T1 tumors have residual disease at second resection. Re-TURBT is recommended within 2–6 weeks if the initial resection is incomplete or if no muscle is present in the specimen. **Citation:** [cite:AUA Bladder Cancer Guidelines 2023], [cite:EAU NMIBC Guidelines 2023]